Leerink Partners stays Outperform on Neurogene (NGNE) following Q4 results; cites de-risked path
Leerink Partners analyst Mani Foroohar reiterated an Outperform rating and $70.00 price target on Neurogene (NASDAQ: NGNE)The analyst commented, "This ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)